RE:REAL DEALBlockbuster is probable. Strongest terms with a Chinese entity I have seen in quite some time for an emerging player. $45M cash up front to the 58% owned subsidiary plus $170M milestone payments to help fund further indications. Establishes a key valuation for the subsidiary as a bonus and secures a long term collaborator with deep pockets. Game changer potentially for BYSD. Tiny float too but the market cap is closing on the billion mark. Funds will be scrambling to get in now.
For once, I timed the bottom on these bio pharmas ... cheers